Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
26 nov. 2024 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
29 févr. 2024 07h30 HE
|
Arbutus Biopharma Corporation
On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101 Plans to initiate a third Phase 2a clinical...
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
15 févr. 2024 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a...
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
08 janv. 2024 07h30 HE
|
Arbutus Biopharma Corporation
Additional data from two on-going Phase 2a clinical trials evaluating imdusiran, our RNAi therapeutic, as a cornerstone therapy in combination with other compounds expected in 2024 Initiation of a...
Arbutus to Present at Jefferies London Healthcare Conference
08 nov. 2023 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
07 nov. 2023 07h30 HE
|
Arbutus Biopharma Corporation
Multiple data presentations upcoming at AASLD – The Liver Meeting®, including preliminary data from Phase 2a clinical trial combining imdusiran, our RNAi therapeutic, with VTP-300, an HBV...
Arbutus Announces CEO, William Collier, to Retire December 31, 2023
07 nov. 2023 07h15 HE
|
Arbutus Biopharma Corporation
Michael J. McElhaugh, Arbutus Co-founder and COO, to Serve as Interim CEO WARMINSTER, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the...
Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
24 oct. 2023 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...
Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference
18 oct. 2023 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023
11 oct. 2023 08h05 HE
|
Arbutus Biopharma Corporation
Imdusiran data will be highlighted in late breaking presentation WARMINSTER, Pa., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage...